EY-Parthenon: 54% of GLP-1 Users Now Take Them for Weight Loss, Surpassing Other Uses

3.0 · 9d ago · US · FINANCE

The Facts

  • About 54% of people taking semaglutide medications such as Ozempic and Wegovy use them to lose weight, overtaking the share using them for other medical reasons, according to EY-Parthenon. CBS News only
  • EY-Parthenon's survey covered nearly 15,000 people, including 3,602 current or former GLP-1 users. CBS News only
  • 63% of GLP-1 users report eating fewer sweet snacks and 57% report eating fewer salty snacks. CBS News only
  • 72% of GLP-1 users sized down in clothing after rapid weight loss; about half increased spending on fitness services and 46% switched apparel brands. CBS News only
  • EY-Parthenon says broader access, including a pill form and lower prices, has led more younger, lower-income and male consumers to use the drugs. CBS News only
Dive deeper · 3 more factsShow less
  • A Trump administration agreement last year with Eli Lilly and Novo Nordisk lowered the cost of Ozempic and Wegovy to $150-$350 per month from roughly $1,000; the Medicare GLP-1 Bridge program offers eligible beneficiaries access for $50 a month. CBS News only
  • Researchers at the Wharton School are starting a study on whether GLP-1s reduce risky financial decisions such as luxury purchases or gambling by affecting the brain's reward system. CBS News only
  • Don Johnson of EY-Parthenon said manufacturers and retailers are adding shelf space for GLP-1-specific foods, protein-enhanced items and smaller portions. CBS News only

Context

A new EY-Parthenon survey finds weight loss has become the most common reason Americans take GLP-1 drugs, ahead of diabetes and other medical uses. The consulting firm reports changes in food, apparel and fitness spending among users.

EY-Parthenon links wider adoption to lower prices, new forms such as pills, and Medicare access. Separately, Wharton researchers plan a study on whether the drugs affect impulsive spending.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 1.

4 Science & Tech Analyst This is a consulting-firm survey report on consumer trends with moderate significance for consumers and retail, though it describes a notable shift in GLP-1 usage and a planned, not yet conducted, Wharton study.
3 Business Analyst This is a consumer survey report from a consulting firm about GLP-1 usage patterns and spending shifts, with a planned academic study, offering limited immediate market impact despite some consumer-sector relevance.
3 News Editor This is a consulting firm survey report on consumer trends rather than a concrete event with immediate broad impact, though its findings on GLP-1 drug use and spending shifts are moderately interesting to many readers.
3 Global Affairs Analyst This is a consulting firm's consumer survey reporting shifts in GLP-1 usage patterns and spending, a niche market-research finding with limited geopolitical significance, though it touches on a notable drug-pricing agreement that is background rather than a new action.
3 Critical Reader This is a consultancy survey reporting consumer behavior trends and a planned study, with no new regulatory action or measurable market-wide change beyond survey findings, so it is minor news with limited impact.
3 Informed Citizen This is a consultancy survey reporting consumer trends and spending shifts, a concrete but limited-impact finding with no new policy action or broad immediate effect on ordinary people.
3 Policy Expert The story reports a private consulting survey's findings on GLP-1 usage and consumer behavior, with only a prior executive pricing agreement referenced as background and a Wharton study merely planned, so no new government action or broad immediate impact occurs.

Sources (2)

← All stories